Literature DB >> 7001124

Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432.

K Oshimi, S Kano, F Takaku, K Okumura.   

Abstract

Streptococcal immunopotentiator OK-432 (NSC-B116209) augmented the natural killer (NK) cell activity of peritoneal exudate cells (PEC) in inbred C57BL/6 mice given ip injections of 0.1 mg OK-432 per mouse. The cytotoxic activity of PEC increased as early as 1 day after inoculation, reached its peak on day 3, and gradually declined thereafter, YAC-1, K562, and MOLT-4 target cells were more sensitive to PEC than were EL 4 and P815 target cells. The elimination of adherent cells by a nylon wool column enriched the proportion of cytotoxic cells among PEC. Nylon wool column-passed PEC were resistant to treatment with anti-Thy 1.2 antibody plus complement and sensitive to anti-asialo GM1 serum plus complement. Because 1:40-diluted rabbit antiserum against glycosphingolipid asialo GM1 is capable of eliminating mouse NK cell activity and is not cytotoxic to killer T-cells, the above results strongly suggest that OK-432 augments the NK cell activity in mice.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7001124

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  34 in total

1.  Preliminary result of mixed bacterial vaccine as adjuvant treatment of hepatocellular carcinoma.

Authors:  Z Y Tang; H Y Zhou; G Zhao; L M Chai; M Zhou; J Z Lu; K D Liu; H F Havas; H C Nauts
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

2.  Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation.

Authors:  M Saito; O Ichimura; M Kataoka; Y Moriya; K Ueno; Y Sugawara; M Nanjo; N Ishida
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Autoimmune kidney disease in MRL/Mp-lpr/lpr mice inhibited by OK-432, a streptococcal preparation.

Authors:  M Mihara; Y Ohsugi
Journal:  Clin Exp Immunol       Date:  1989-10       Impact factor: 4.330

Review 4.  Management of malignant pleural effusions.

Authors:  F Grossi; M C Pennucci; L Tixi; M A Cafferata; A Ardizzoni
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

Review 5.  Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations.

Authors:  Alexander G Raufi; Samuel J Klempner
Journal:  J Gastrointest Oncol       Date:  2015-10

6.  Susceptibility of W/WV mice to murine cytomegalovirus infection.

Authors:  T Ohashi; Y Nawa; Y Minamishima; M Owhashi
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

7.  An adhesive glycoprotein from rat ascites hepatoma cells potentiates natural cytotoxic activity by rat spleen cells.

Authors:  J Y Chen; R Kurano; M Hirashima; H Hayashi
Journal:  Immunology       Date:  1986-05       Impact factor: 7.397

8.  Inhibition of in vitro LAK generation by OK-432.

Authors:  M Yagita; E A Grimm
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  A patient with gastric carcinoma improved remarkably on intraperitoneal OK-432 therapy.

Authors:  H Yamagishi; H Ishibashi; M Kodama; T Tanaka; Y Harada; I Hashimoto
Journal:  Jpn J Surg       Date:  1982

10.  Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma.

Authors:  Tomoyuki Tano; Masato Okamoto; Shin Kan; Koh-Ichi Nakashiro; Shigetaka Shimodaira; Shigeo Koido; Sadamu Homma; Mitsunobu Sato; Tomonobu Fujita; Yutaka Kawakami; Hiroyuki Hamakawa
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.